5 news items
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
ELTX
10 Jun 24
In speaking about these findings, Christopher Haqq, MD, PhD, executive vice president, head of Research
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
23 May 24
, Head of Research and Development, and Chief Medical Officer, added, "These early immunogenicity and biomarker response data from ELI-002 7P continue
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
ELTX
15 May 24
President, Head of Research and Development, and Chief Medical Officer, added, "We have continued to analyze and publish data from our first-in-human
Elicio Therapeutics To Present Updated Clinical T Cell And Antigen Spreading Response Data From The Ongoing AMPLIFY-201 Phase 1 Study Of ELI-002 And Preclinical Data On ELI-007 And ELI-008 At The AACR Annual Meeting
ELTX
5 Apr 24
response that may lead to enhanced clinical activity," said Christopher Haqq, M.D., Ph.D., Elicio's Executive Vice President, Head of Research
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
ELTX
5 Apr 24
Christopher Haqq, M.D., Ph.D., Elicio's Executive Vice President, Head of Research and Development, and Chief Medical Officer. "Following positive early
- Prev
- 1
- Next